Company Description

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases.

It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.

The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023.

Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

Curanex Pharmaceuticals Inc

Country	United States
Founded	2018
IPO Date	Aug 26, 2025
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Jun Liu

Contact Details

Address: 2 Jericho Plaza, Suite 101B Jericho, New York 11753 United States
Phone	718 673 6078
Website	curanexpharma.com

Stock Details

Ticker Symbol	CURX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.00
CIK Code	2025942
CUSIP Number	23126K106
ISIN Number	US23126K1060
Employer ID	83-0741390
SIC Code	2834

Key Executives

Name	Position
Jun Liu	Chief Executive Officer, President and Chairman
Dian Ying Jing	Secretary
Haiyan Yang	Chief Financial Officer and Treasurer
Dr. Liqin Xie Ph.D.	Chief Operating Officer
Dr. Ning Zhang Ph.D.	Chief Technology Officer
Dr. Huijuan Zhong Ph.D.	Chief Science Officer and Director

Latest SEC Filings

Date	Type	Title
May 14, 2026	8-K	Current Report
May 14, 2026	10-Q	Quarterly Report
May 7, 2026	8-K	Current Report
Apr 2, 2026	8-K	Current Report
Mar 30, 2026	10-K	Annual Report
Mar 6, 2026	8-K	Current Report
Jan 5, 2026	8-K	Current Report
Nov 17, 2025	10-Q	Quarterly Report
Nov 17, 2025	NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
Nov 6, 2025	8-K	Current Report

View All SEC Filings